Travelan® has been shown in clinical trials to significantly decrease the risk of Travellers’ Diarrhoea and to decrease the symptoms of minor gastrointestinal disorders associated with Travellers’ Diarrhoea. Travelan® is an antimicrobial which underwent Controlled Human Infection Model (CHIM) studies. These studies were double-blind, placebo-controlled medical trials conducted in Europe and the USA. The trials showed protection of up to 90% against infection with E.coli (ETEC) and the development of TD. The trials have also shown that people who received Travelan® and subsequently were infected by E.coli had significantly less discomfort and diarrhoea, compared to those who did not receive Travelan®.
In addition recent studies performed by the US Defense Force show that the anti-ETEC antibodies in Travelan® are cross-reactive and react against other diarrhoea-causing pathogenic bacteria such as Campylobacter, other strains of Enterotoxigenic E.coli and Shigella – all potential causes of Travellers’ Diarrhoea.